Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
Merck Eyes Revolution Medicines in a Potential $32 Billion Deal
11:14am, Friday, 09'th Jan 2026
Merck (MRK) is reportedly in talks to acquire Revolution Medicines (RVMD) for $28-$32 billion or more. This acquisition aims to strengthen MRK's oncology pipeli
Here's What We Expect From AbbVie's Immunology Segment in Q4
08:46am, Friday, 09'th Jan 2026
ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.
First Look: GM's $7.1B EV Charge, Paramount's $30 WBD Bid
07:38am, Friday, 09'th Jan 2026
Stock News xAI under fire over Grok image edits: Elon Musk's xAI (private) restricted Grok's image generation/editing on X to paying users after the tool was us
Clear Harbor Asset Management LLC Decreases Stake in AbbVie Inc. $ABBV
05:34am, Friday, 09'th Jan 2026
Clear Harbor Asset Management LLC trimmed its position in shares of AbbVie Inc. (NYSE: ABBV) by 7.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned
Ferguson Wellman Capital Management Inc. Purchases 3,260 Shares of AbbVie Inc. $ABBV
05:34am, Friday, 09'th Jan 2026
Ferguson Wellman Capital Management Inc. increased its position in AbbVie Inc. (NYSE: ABBV) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commi
AbbVie Inc. $ABBV Shares Bought by Duncker Streett & Co. Inc.
04:52am, Friday, 09'th Jan 2026
Duncker Streett and Co. Inc. lifted its position in AbbVie Inc. (NYSE: ABBV) by 17.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
01:52am, Friday, 09'th Jan 2026
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32
AbbVie: The Dividend Does Not Lie
12:07pm, Thursday, 08'th Jan 2026
AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its pa
AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.
07:38am, Thursday, 08'th Jan 2026
Shareholders in both drugmakers appear disappointed that a deal may not happen.
Breakfast News: Defense Stocks Whipsaw
07:30am, Thursday, 08'th Jan 2026
Trump puts pressure on defense contractors, Globus Medical soars on preliminary results, and more
AbbVie Inc. $ABBV Stock Holdings Increased by CX Institutional
05:04am, Thursday, 08'th Jan 2026
CX Institutional lifted its holdings in AbbVie Inc. (NYSE: ABBV) by 30.8% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owne
Why Revolution Medicines Shares Are Sliding After Hours On Wednesday
03:13am, Thursday, 08'th Jan 2026
Shares of Revolution Medicines tumbled in after-hours trading on Wednesday after AbbVie denied reports that it was in talks to acquire the cancer-drug developer.
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
02:58pm, Wednesday, 07'th Jan 2026
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
AbbVie Near Deal for Revolution Medicines
02:48pm, Wednesday, 07'th Jan 2026
The cancer-drug biotech firm has a market value around $16 billion.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 07'th Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
